H ypertension is a leading cause of morbidity and mortality worldwide, which is considered as a major risk factor for stroke, coronary heart disease, and chronic kidney disease. 1 Although numerous studies have stressed the multifactorial nature of hypertension, the pathogenesis of hypertension remains largely unknown. Emerging evidence indicates that epigenetics plays a vital role in the cause of hypertension. 2 Among them, HDAC (histone deacetylase)-mediated epigenetic processes in vascular homeostasis and cardiovascular disease have attracted much attention. Sirtuin 6 (SIRT6), one member of the SIRT family of class III HDACs that are highly conserved NAD + -dependent deacetylases, is demonstrated to control mechanisms responsible for the longevity and stability of the genome, supporting the beneficial role in the context of age-associated diseases. 3, 4 Recent studies have indicated the involvement of SIRT6 in cardiac hypertrophy 5 and atherosclerosis. 6 However, the role of SIRT6 in the pathogenesis of hypertension and associated organ damages keeps unclear. More importantly, it still remains the key challenge to discover new targets of SIRT6 and explore related molecular signaling pathways under these pathogenic conditions.
Endothelial dysfunction is a common problem associated with hypertension and is considered a precursor to the development of micro and macrovascular complications. 7 Moreover, endothelial dysfunction is also recognized as a major contributor to the crosstalk between cardiac and renal dysfunction. 8 Therefore, further elucidating the role of SIRT6 on the regulation of endothelial function will offer the possibility to identify epigenetic targets specific for hypertension and its complications. In this study, we found that endothelial SIRT6 levels were significantly reduced in 2 independent hypertension models: desoxycorticosterone acetate (DOCA)/salt-induced and Ang II (angiotensin II)-induced hypertensive mice. Endothelialspecific deletion of SIRT6 in mice significantly enhanced blood pressure, exacerbated endothelial dysfunction and cardiorenal injury in experimental hypertension. We further found that SIRT6 induced the expression of GATA5 (GATA-binding protein 5), which is identified as a new gene involved in the regulation of blood pressure. Endothelial-specific loss of GATA5 in mice leads to vascular endothelial dysfunction and hypertension by disrupting several pathways essential for proper endothelial signaling and homeostasis. 9 Mechanistically, SIRT6 promoted the expression of GATA5 through inhibiting the transcription of Nkx3.2 (NK3 homeobox 2), a transcriptional repressor, 10 by deacetylating histone H3K9 (histone H3 lysine 9). Collectively, our studies discover a previously unrecognized role of SIRT6 in protecting vascular endothelium against hypertension and associated organ injuries and highlight a novel pathway with potential therapeutic relevance.
Methods
The authors declare that all supporting data are available within the article and its Online Data Supplement.
A detailed Methods section can be found in the Online Data Supplement.
Results

Levels of Endothelial SIRT6 Were Significantly Reduced in 2 Independent Hypertension Models: DOCA/Salt-Induced and Ang II-Induced Hypertensive Mice
To investigate the broad implications of SIRT6 signaling in hypertension, 2 independent hypertension models, DOCA/saltinduced and Ang II-induced hypertensive mice were used in this study. We found that SIRT6 was downregulated in the aorta, kidney, and heart from both mouse models of experimental hypertension ( Figure 1A ). Immunofluorescence staining further observed that SIRT6 was mainly expressed in the nucleus, and the level of SIRT6 was markedly reduced in aortic and glomerular 
Novelty and Significance
What Is Known?
• Endothelial dysfunction, commonly associated with hypertension, is a precursor to the development of micro and macrovascular complications.
• Epigenetics plays a vital role in the cause of hypertension.
• Sirt6 (sirtuin 6) is a member of the SIRT family of class III NAD+-dependent HDAC (histone deacetylase).
What New Information Does This Article Contribute?
• Endothelium-specific SIRT6 deletion in mice exacerbates desoxycorticosterone acetate/salt-induced and Ang II (angiotensin II)-induced hypertension, endothelial dysfunction, and cardiorenal injuries.
• SIRT6 regulates the transcriptional repressor Nkx3.2 (NK3 homeobox 2) by deacetylating H3K9 (histone H3 lysine 9). • SIRT6-medicated Nkx3.2/GATA5 (GATA-binding protein 5) signaling is one of the critical signal transduction pathways in the regulation of endothelial function.
Endothelial dysfunction is an important risk factor for the development of hypertension and associated organ damages. Thus, identification of potential therapeutic targets for preventing endothelial dysfunction has major clinical importance. In this study, we found that endothelium-specific deletion of SIRT6 HDAC in mice significantly exacerbated hypertension, endothelial dysfunction and cardiorenal injury in experimental hypertension, including desoxycorticosterone acetate/salt-induced or Ang II-induced hypertension. Functionally, SIRT6 has pleiotropic protective actions in endothelial cells including promoting NO release, reducing cellular permeability and facilitating autophagy. At a mechanistic level, SIRT6 promotes the expression of GATA5 through inhibiting Nkx3.2 transcription by deacetylating histone H3K9, thereby regulating GATA5-mediated signaling pathways to protect against endothelial injury. These findings uncover a previously unrecognized role of SIRT6 in protecting vascular endothelium against hypertension and associated organ injuries, thereby highlighting a novel pathway of potential therapeutic relevance. endothelial cells from DOCA/salt-induced ( Figure 1B) or Ang II-induced hypertensive mice (Online Figure I ) by colocalization of SIRT6 with endomucin, a known endothelial cell marker. We further confirmed the reduction of SIRT6 in sections of kidney biopsy samples from patients with hypertensive nephropathy but without any pathological findings that would indicate the presence of any other type of kidney disease ( Figure 1C ). In vitro, Ang II ( Figure 1D and Online Figure II) , ET-1 (endothelin-1; Figure 1E ; Online Figure III ), or oxidative stress induced by H 2 O 2 ( Figure 1F and Online Figure IV) We generated conditional knockout mice in which SIRT6 is specifically ablated in endothelial cells by using Cre-LoxP recombination system. Tie2-Cre mice were crossed with SIRT6 fl/fl mice showed a slight increase tendency but no statistical difference in systolic blood pressure, diastolic blood pressure, and mean blood pressure at 4 months of age. However, at 8 and 12 months of age, the blood pressure in Cre + /SIRT6 fl/fl mice much higher than their age-matched controls (Online Table IV) . Compared with controls, Cre + /SIRT6 fl/ fl mice (10-12 weeks of age) with DOCA/salt treatment for 3 weeks after unilateral nephrectomy exhibited a more significant increase in systolic blood pressure, diastolic blood pressure and mean blood pressure (Table) . Similar results were also found in Ang II-induced hypertensive mice (Online Figure V) .
Endothelial-Specific Deletion of SIRT6 Exacerbated Endothelial Dysfunction and Cardiorenal Injuries in DOCA/Salt-Induced Hypertensive Mice
Endothelial function was evaluated by the vascular reactivity. Among all groups of mice, no significant difference was found at the basal level of endothelium-dependent relaxation responses induced by acetylcholine at concentration from 10 Figure 2C ). There was no difference in the endothelium-independent vasorelaxation responses induced by sodium nitroprusside in mesenteric resistance arteries isolated from these groups of mice ( Figure 2D ). Moreover, almost all the endothelium-dependent vasorelaxation responses were blocked by L-nitro-arginine methyl ester (10 -4 mol/L), a nonselective NO synthase inhibitor ( Figure 2E ). These data suggest that SIRT6 is a crucial regulator of endothelial function.
In the kidney, we found that the kidney weight-to-body weight ratio and the levels of urine albumin-to-creatinine ratio were further increased in DOCA/salt-treated Cre (Table) . Endothelial-specific deletion of SIRT6 exacerbated mesangial matrix expansion and the reduction in the density of glomerular endothelial fenestrae ( Figure 2F ) in DOCA/salt-treated mice.
In the heart, we examined cardiac functions by echocardiography. As shown in Table, DOCA/salt treatment significantly decreased cardiac function in Cre
+/+ mice as evidenced by decreases in ejection fraction % and fractional shortening %, which were aggravated in Cre
fl/fl mice. We also measured cardiac remodeling-related parameters and found that endothelial-specific deletion of SIRT6 induced more left ventricular hypertrophy (Table) and arterial wall thickness ( Figure 2G ). Morphological examinations further confirmed the more hypertrophic remodeling and perivascular fibrosis in the heart from DOCA/salt-treated Cre
fl/fl mice ( Figure 2G ).
SIRT6 Ameliorated Endothelial Injuries In Vitro
To better explore the molecular mechanisms by which SIRT6 regulates endothelial function, Ang II was used as one representative stimulus which is greatly implicated in the pathogenesis of endothelial dysfunction in in vitro studies. Overexpression of SIRT6 by a SIRT6-adenovirus transfection ( Figure 3A ) markedly ameliorated Ang II-induced abnormal endothelial cell permeability ( Figure 3B ) accompanied by the increased level of ZO-1 (zonula occluden-1) and the reduced levels of MMP2 (matrix metalloprotease) and MMP9 in RGECs (Online Figure VI) . Immunofluorescence analysis further clarified that the damaged ZO-1 protein was recovered by overexpression of SIRT6 (Online Figure VI) . We also found that SIRT6 alleviated endothelial senescence as evidenced by the reduced expressions of P16 and P21, markers of endothelial cell senescence ( Figure 3C ), and the reduced number of SA-β-gal (senescenceassociated β-galactosidase)-positive cells in RGECs with Ang II treatment (Online Figure VII) . In addition, we also examined whether SIRT6 regulates autophagy. As shown in Figure 3D , mildly upregulated LC3 (microtubule-associated protein 1 light chain 3)II/I ratio and downregulated P62 expression were observed in the Ang II groups compared with the corresponding controls. Overexpression of SIRT6 further increased the ratio of LC3II/I ratio while further decreasing the level of P62 in RGECs with Ang II treatment. Moreover, we also confirmed In RGEC transduced with Ad-GFP-RFP-LC3, Ang II treatment slightly increased the number of autophagosomes (yellow puncta) and autolysosomes (red puncta) compared with the corresponding controls. More significant increases in autolysosomes (red puncta) were observed in the Ang II /Ad-SIRT6 group ( Figure 3E ). The facilitating autophagy by SIRT6 was also demonstrated by transmission electron microscopy ( Figure 3F ).
To further verify the role of SIRT6-induced autophagy on the regulation of endothelial function, pharmacological inhibition of autophagy with 3-MA (3-methyladenine) was used in this study. Overexpression of SIRT6 ameliorated Ang II-induced apoptosis by flow cytometry ( Figure 3G ) and caspase-3 activity ( Figure 3H ) analyses, mitochondrial dysfunction by the measurement of mitochondrial membrane potential ( Figure 3I ), and senescence ( Figure 3J ), which were reversed by 3-MA. In addition, except that SIRT6 induced autophagy and reduced apoptosis (Online Figure VIII) , the beneficial effects of SIRT6 overexpression in human umbilical vein endothelial cells on the production of NO in both lysate ( Figure 3K ) and medium ( Figure 3L ) was also counteracted by 3-MA. Moreover, overexpression of SIRT6 inhibited the Ang II-induced mRNA levels of VCAM-1 (vascular cell adhesion molecular 1) and ICAM-1 (intercellular adhesion molecule 1), which was blocked by 3-MA (Online Figure IX) . Finally, although we did not provide more data to identify the action of SIRT6 on specific compartments of the cardiorenal system in mice, overexpression of SIRT6 by lentiviral gene delivery in mice ameliorated Ang II-induced hypertension, cardiac dysfunction, and proteinuria, which were abolished by 3-MA administration (Online Figure X) , supporting the protective role of SIRT6-induced autophagy.
SIRT6 Indirectly Regulated GATA5 Expression
Considering that SIRT6 is a highly specific deacetylase that mainly targets H3K9 and H3K56 (histone H3 lysine 56) for the regulation of gene expression by modifying chromatin structure, 11, 12 we then measured the levels of H3K9 acetylation (H3K9ac) and H3K56 acetylation (H3K56ac) in DOCA/ salt-induced hypertensive mice. The level of H3K9ac rather than H3K56ac was significantly increased in isolated glomeruli from DOCA/salt-treated Cre + /SIRT6 +/+ mice, and a more significant increase was observed in those from DOCA/salttreated Cre + /SIRT6 fl/fl mice ( Figure 4A ). Immunofluorescence staining further confirmed a more increase in the level of H3K9ac in glomerular endothelial cells from DOCA/salttreated Cre + /SIRT6 fl/fl mice ( Figure 4B ). Importantly, we also observed that the level of H3K9ac was significantly increased in renal biopsies from patients with hypertensive nephropathy by IHC (immunohistochemistry) staining ( Figure 4C ). Furthermore, a more significant reduction of GATA5, a transcription factor that regulates blood pressure, was observed in isolated glomeruli ( Figure 4D ) or glomerular endothelial cells ( Figure 4E ) from DOCA/salt-treated Cre + /SIRT6 fl/fl mice compared with their controls, indicating that SIRT6 regulates GATA5 expression. Considering that SIRT6 could not bind to GATA5 by coimmunoprecipitation assay (Online Figure  XI) , we then examined whether SIRT6 controls GATA5 transcription by regulating H3K9ac (H3K56ac) in the promoter of GATA5. By chromatin immunoprecipitation (ChIP) assay, we found that although H3K9ac and H3K56ac could combine to the promoter of GATA5, endothelial-specific deletion of SIRT6 had no effects on the levels of H3K9ac or H3K56ac in the promoter of GATA5 in isolated glomeruli from different groups of DOCA/salt-treated mice ( Figure 4F ). Similar results were also found in Ang II-induced hypertensive mice (Online Figure XII) . Therefore, we conclude that SIRT6 may not directly regulate GATA5 expression.
SIRT6 Promoted the Expression of GATA5 Through Inhibiting Nkx3.2 Transcription by Deacetylating Histone H3K9
Consistently, in vitro, overexpression of SIRT6 in RGECs counteracted the effects of Ang II on the levels of H3K9ac and GATA5 ( Figure 5A ). We further performed ChIP assay and found that overexpression of SIRT6 had no effects on the level of H3K9ac and H3K56ac in the promoter region of GATA5 ( Figure 5B ), confirming that SIRT6 could not directly regulate GATA5 transcription in vitro. Interestingly, Nkx3.2, a transcriptional repressor, had the opposite expression patterns as compared with GATA5 ( Figure 5C ), encouraging us to examine whether SIRT6 mediates GATA5 expression by transcriptional regulation of Nkx3.2. It was found that SIRT6 had no interaction with Nkx3.2 by coimmunoprecipitation, but SIRT6 could bind to the promoter of Nkx3.2 (Online Figure  XIII) . We then examined whether SIRT6 controls Nkx3.2 transcription by regulating H3K9ac (H3K56ac) in the promoter of Nkx3.2. By ChIP assay, we found that both H3K9ac and H3K56ac could bind to the promoter of Nkx3.2, but only the level of H3K9ac in the promoter of Nkx3.2 was increased in RGECs with Ang II treatment, which was reduced by overexpression of SIRT6 ( Figure 5D ). Moreover, by ChIP assay, we also confirmed that SIRT6 controlled Nkx3.2 transcription by regulating H3K9ac in the promoter of Nkx3.2 in isolated glomeruli from different groups of both Ang II-induced and DOCA-induced hypertensive mice (Online Figure XIV) .
To further study the relationship between SIRT6, GATA5, and Nkx3.2, gene silencing of Nkx3.2 or SIRT6 was performed. It was found that gene silencing of Nkx3.2 recovered the level of GATA5 ( Figure 5E ). SIRT6 knockdown ( Figure 5F ) induced Nkx3.2 expression and reduced GATA5 expression, whereas gene silencing of Nkx3.2 rescued the reduction of GATA5 in SIRT6-deficient RGECs ( Figure 5G ), indicating that SIRT6 regulates GATA5 expression by targeting transcriptional repressor Nkx3.2. In addition, gene silencing of Nkx3.2 could decrease the endothelial cell permeability ( Figure 5H ) and recover the expression of ZO-1 ( Figure 5I ) in RGECs under Ang II or SIRT6-deficient condition. In human umbilical vein endothelial cells, SIRT6 deficiency reduced the level of p-eNOS (endothelial NO synthase), which was rescued by gene silencing of Nkx3.2 under Ang II or SIRT6-deficient condition, as well as the production of NO in both lysate and medium (Online Figure XV) .
In Vivo Overexpression of SIRT6 by Lentiviral Gene Delivery Prevented DOCA/Salt-Induced Hypertension and Associated Cardiorenal Injury in Mice
To examine genetic therapeutic efficiency targeting to SIRT6 in experimental hypertension, recombinant lentivirus vectors pGLV3 (third-generation lentivirus vector plasmids) harboring SIRT6 were delivered into DOCA/salt-treated Cre + / SIRT6 fl/fl mice by means of tail vein injection. The efficiency of gene transfection was confirmed by mRNA analysis showing that mice received SIRT6 lentivirus markedly increased the level of SIRT6 in the kidney and aorta (Online Figure XVI) . Overexpression of SIRT6 significantly reduced blood pressure ( Figure 6A ), improved endothelium-dependent vasorelaxation ( Figure 6B ), ameliorated renal injury as evidenced by reduced levels of urine albumin-to-creatinine ratio ( Figure 6C ), decreased mesangial expansion, and increased density of glomerular endothelial fenestrae in DOCA/salt-treated Cre + / SIRT6 fl/fl mice ( Figure 6D ). In addition, overexpression of Figure XVII) . Collectively, our studies demonstrate that rescue therapy with SIRT6 promotes kidney and cardiac repairs in hypertensive mice.
Discussion
HDACs are a family of enzymes to balance the acetylation activities of histone acetyltransferases on chromatin remodeling and are critical for the regulation of gene transcription. HDACs consist of 18 members grouped into 4 classes on the basis of substrate, structure, sequence homology, and domain organization. 13 Among them, SIRTs (also known as class III HDACs) are highly conserved NAD + -dependent deacetylases or ADPribosyl transferases related to the Sir2 gene. Currently, 7 SIRTs (SIRT1-7) are identified in mammals, and each of them has different subcellular localizations, targets, and functions. 14, 15 In this study, we found that endothelial-specific SIRT6 knockout (Cre −/− mice were indiscernible from their wide-type littermates in the degree of proteinuria levels. However, at 2 months of age, SIRT6 −/− mice developed slight proteinuria compared with their age-matched controls, which was significantly increased by 7 months of age. 16 Collectively, results by our and other groups support the beneficial role of SIRT6 in the context of age-associated diseases. Under the pathological stress of hypertension, endothelial-specific deletion of SIRT6 further exacerbated endothelial dysfunction and cardiorenal injuries in hypertensive mice, indicating the importance of endothelial SIRT6 in maintaining endothelial functions.
Hypertension is a complex multifactorial disease which is influenced by genetic and environmental factors. Various models of experimental hypertension have been primarily developed using the etiological factors to mimic hypertensive responses observed in humans. To comprehensively investigate the role of endothelial SIRT6 in hypertension, 2 independent hypertension models were performed. One is DOCA/salt-induced hypertension that shows a markedly depressed reninangiotensin system and thus is regarded as a low renin model of hypertension. 17 It provides a useful platform for investigating hypertension complications, such as glomerulosclerosis, proteinuria, impaired endothelium-dependent vasodilatation, and cardiac hypertrophy. In this model, elevated vasopressin, oxidative stress, and ET-1 are identified. 18, 19 Another model is Ang II-induced hypertension by chronic infusion of Ang II which is traditionally involved in modulating blood pressure and electrolyte homeostasis. It is also greatly implicated in the pathogenesis of endothelial dysfunction and vascular remodeling. 20, 21 In this study, one of the most important findings was the consistent reduction of SIRT6 in endothelial cells in 2 independent experimental hypertension models, indicating that the reduction of SIRT6 may be a common feature of different types of experimental hypertension.
By establishing the endothelial-specific SIRT6 knockout mice, we confirmed that the endothelial-specific loss of SIRT6 significantly enhanced blood pressure and associated cardiorenal injuries in hypertensive mice. Functionally, SIRT6 ameliorated endothelial senescence and apoptosis, reduced endothelial cell permeability, and increased endothelium-dependent vasodilatation and vascular NO bioavailability under pathogenic conditions. SIRT6 can also promote endothelial autophagy. Autophagy is a fundamental process to maintain normal vessel wall biology. 22 Dysregulation of autophagy is involved in the pathogenesis of cardiovascular disease. 23 Multiple genetic interventions that limit autophagic flux at the whole-body level or in specific compartments of the cardiovascular system are associated with the spontaneous development of cardiovascular disorders. Although studies have indicated that insufficient autophagic activity impairs normal heart and vessel function and is associated with accelerated aging process, 24 autophagic activity is differentially regulated depending on the nature and the duration of the stress in various pathological conditions. 25 In addition, the role of stress-mediated autophagy in cardiac disorders is more complex. Although studies have clearly revealed that Ang II increases autophagy, the function of autophagy during AngII-induced cardiac hypertrophy keeps controversial. The prosurvival or prodeath effect of autophagy may finally be determined by different types of cells, the identity of the cellular components being degraded, as well as the timing and magnitude of autophagic activity relative to other essential cellular processes. It should be noted that although it is still a matter of debate, an increasing number of studies indicate that upregulation of autophagy may play a protective role to antagonize Ang II-induced cardiac hypertrophy. ATG5 (autophagy-related 5) haplodeficiency decreases the Ang II-induced mitophagy in macrophages and increases cardiac injury and the inflammatory response to Ang II. 26 A recent study has demonstrated that cardiomyocyte-specific Mst1 (mammalian sterile 20-like kinase 1) knockout alleviates Ang II-induced cardiac injury by enhancing cardiomyocyte autophagy. It was found that the enhanced autophagy in cardiomyocytes subjected to Ang II treatment is a compensatory protective mechanism and the further elevated cardiomyocyte autophagy by Mst1 knockout plays beneficial effects. 27 In endothelial cells, Ang II induces autophagy, senescence, and apoptosis of human umbilical vein endothelial cells progressively, and autophagy presents an early protective effect on vascular endothelial damage in response to Ang II, which is consistent with recent studies showing that autophagy limits the detrimental effects of etiological factors on endothelial dysfunction. 28, 29 In this study, the beneficial effects of SIRT6 overexpression on endothelial function and cardiorenal function were attenuated by pharmacological inhibition of autophagy with 3-MA, supporting the protective role of SIRT6-induced autophagy. Consistently, a recent study has also found that SIRT3 activation is essential to improve autophagy flux by reducing the acetylation modification on FoxO1 (forkhead box O1), which, in turn, alleviates Ang II-induced murine myocardial hypertrophy.
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GATA5 belongs to the GATA family of transcription factors characterized by highly evolutionarily conserved zincfinger DNA-binding domains. 31, 32 Studies have implicated a role of GATA5 during mammalian embryogenesis, including proper heart development and gender-specific regulation of female genitourinary tract formation. 33, 34 GATA5 is recently identified as a novel regulator of blood pressure. GATA5 deficient mice have a hypertensive phenotype that reproduces several of the features of human hypertension, including vascular dysfunction, salt sensitivity, and target-organ damage. 9 In this study, although we found that SIRT6 positively regulated GATA5 expression and ChIP assay showed that H3K9ac and H3K56ac bound to the promoter of GATA5 in RGECs, no significant changes on the binding to its promoter were observed under Ang II condition with or without SIRT6 overexpression, indicating that SIRT6 may not directly regulate GATA5 expression. Mechanistically, we found that Nkx3.2 and GATA5 genes displayed reciprocal expression patterns. Nkx3.2, a transcriptional repressor, 10 is a member of the NK family and is expressed during embryogenesis in a variety of mammalian model organisms. 35 Nkx3.2 can be regulated by epigenetic modification. 36 Moreover, Nkx3.2 is also reported to repress BMP-mediated induction of GATA family members, including GATA4, GATA5, and GATA6. 37 Therefore, we wondered whether SIRT6 regulates GATA5-mediated signaling by epigenetic modifications of Nkx3.2. By binding to its promoter and deacetylating H3K9ac at its promoter, SIRT6 reduced the expression of Nkx3.2. The inhibition of Nkx3.2 rescued GATA5 expression and the functional defects in SIRT6-deficient RGECs, indicating that Nkx3.2 reduces GATA5 expression. However, it keeps unclear whether Nkx3.2 represses GATA5 gene induction by directly binding to the regulatory regions of GATA5 or by repressing the expression of an activator(s) of GATA5. Further studies are needed to clarify the precise regulatory mechanisms of GATA5 by suppression of the transcription of Nkx3.2.
Finally, we provide direct evidence showing that overexpression of SIRT6 has therapeutic potential for DOCA/salt-induced hypertension, endothelial dysfunction, and cardiorenal injuries. Moreover, we also found that perivascular fibrosis in the heart was improved by overexpression of SIRT6 in consistent with our results showing that endothelial-specific deletion of SIRT6 exacerbated perivascular fibrosis in hypertensive mice. In fact, the high prevalence of perivascular fibrosis in animal models of cardiovascular disease 38 and in human patients with cardiomyopathic conditions 39 suggest the involvement of vascular cells in fibroblast activation. After myocardial injury, vascular endothelial cells may contribute to fibrotic cardiac remodeling. Induction of adhesion molecules, such as ICAM-1, in stimulated microvascular endothelial cells may play an important role in recruitment of fibrogenic macrophages and lymphocytes in both infarcted and pressure-overloaded hearts. 40 Considering that SIRT6 can reduce the levels of ICAM-1 and VCAM-1 in endothelial cells, we suggest that endothelial SIRT6 may play a direct role of improving perivascular fibrosis. In addition, recent studies have also found that endothelialspecific SIRT3 deletion impairs glycolysis and angiogenesis, and increases perivascular fibrosis in the coronary artery. 41 Deletion of SIRT2 markedly exaggerates cardiac hypertrophy and fibrosis in aged mice and Ang II-infused mice by the reduction of AMPK activation. 42 Therefore, further studies are also needed to examine whether the member of SIRTs share the similar mechanisms to prevent perivascular fibrosis.
Collectively, our studies for the first time demonstrate that SIRT6 prevents pathological hypertension and its complications by maintaining endothelial function, at least in part, through epigenetic regulation of Nkx3.2-mediated GATA5 signaling (Figure 7 ), suggesting that SIRT6 may be an innovative therapeutic strategy for treating patients with hypertension. Figure 7 . Schematic depicting SIRT6 (sirtuin 6) deficiency exacerbates endothelial dysfunction, hypertension, and associated cardiorenal injury via targeting Nkx3.2 (NK3 homeobox 2)-GATA5 (GATA-binding protein 5) signaling. Under pathological conditions, SIRT6 reduction leads to the increased levels of H3K9 (histone H3 lysine 9) acetylation (H3K9ac) in the promoter of Nkx3.2, thereby enhancing the transcription of Nkx3.2 gene. The activation of Nkx3.2 reduces the level of GATA5, consequently resulting in endothelial dysfunction which contributes to the development of hypertension and associated cardiorenal injury.
